New World Evidence Data Market

Category : Healthcare & Life Sciences Reports | Delivery Format : PDF,PPT | Publisher: Reports and Insights | Pages : 200

To learn more about this report, request a free sample copy

New World Evidence Data Market Overview

The report is titled ‘New World Evidence Data Market: Opportunity Analysis and Future Assessment 2020-2028’. An overview of conceptual frameworks, analytical approaches of the new world evidence data market is the main objective of the report, which further consists of the market opportunity and insights of the data involved in the making of the respective market. The new world evidence data market is expected to grow at a significant rate in the near future.

The global new world evidence data market in 2020 is estimated for more than US$ 883.5 Bn and expected to reach a value of US$ 2,607.4 Bn by 2028 with a significant CAGR of 14.6%.

New World Evidence Data Introduction

Basically, real-world data (RWD) can be defined as the data which is regularly compiled from different sources associated with a consignment of healthcare and patient health conditions. By the same token, real-world evidence (RWE) may be defined as the clinical evidence about the pharmaceutical product acquired for evaluation of real-world data along with its usage, potential advantages, or hazards.

In addition to that, there has been a huge chunk of health-related data to gather and store, and this data is stored in various kinds of devices such as biosensors, computers, mobile devices, smart wearable, and many more.

Although notably, the huge chunk of healthcare data is of great importance as it gives answers to many questions in the healthcare setting which were previously infeasible as well as it helps in new clinical trials and drug development processes.

Along with that, the real-world evidence data also helps in the development of new pharmaceutical products and their approval as the data can be analyzed and the results of the analysis can be applied in the development process. Owing to this, the global new world evidence data market is projected to boost rapidly in the near future.

New World Evidence Data Market Dynamics

The growing usage of the electronic health record systems as an observational system for the patient is primarily flourishing the global new world evidence data market. For instance, according to Health IT Buzz, in September 2016, in the United States, nearly 96% of hospitals and 78% of doctors use certified electronic health record systems.

In addition to that, the constantly growing need for enhanced medical products and devices and increasing count of novel clinical trials for the approval of new drug products is further projected to fuel the growth of the new world evidence data market in the near future. Along with that, there is a rising trend of targeted therapies as well as the development of new and improved treatments, which is also estimated to lead to the rapid growth of the new world evidence market during the forecast period.

Other than that, the huge shift in the modern-day world, from volume-based data to value-based data is also acting as a major driver that is expected to further propel the growth of the global new world evidence data market in the near future. Attributing to all such factors, the new world evidence data market is anticipated to witness significant growth in the coming years.

Further, the use of new clinical trials for the approval of the drugs has also thrived the target market. In addition, the development of new treatment and targeted therapies have also led to the growth of the global new world evidence data market. Moreover, the use of the social media platforms to share the new therapies and data has also evolved the target market. Furthermore, moving from volume-based data to value-based data has also helped to grow the global new world evidence data market.

New World Evidence Data Market Segmentation

By Component:

Dataset (Claims, Clinical, Pharmacy, Patient), 

Services

By Therapeutic Area: 

Oncology

Cardiovascular

Immunology 

By End User:

Pharmaceuticals

Medical Devices

Payers

Providers

By Region:

North America

Europe

Asia Pacific

Latin America

Middle East

Africa

New World Evidence Data Market for the Use of New Clinical Trial Overview

Many years of consistent research and development is done by pharmaceutical companies to introduce new drug or molecule in the market. For which pharmaceutical companies invest a huge amount of money from their revenue in research and development in which the probability of getting a positive results is very low. Owing to companies mainly in pharmaceutical and biotech, the usage of Real-world evidence (RWE) insights which are very useful for life-cycle management and for the development of drugs is growing at a rapid rate which increases the expenditure on clinical trials and innovation. Presently, the usage of a clinical-genomic database with tumor sequencing information for targeted drug development and cancer discovery studies is done by big pharmaceutical companies.

New World Evidence Data Market Competitive Landscape

Some of the key participating players in the global new world evidence data market are Oracle, IQVIA, International Business Machines Corporation, Syneos Health, ICON, Pharmaceutical Product Development, Optum, Cognizant, SAS, and Flatiron Health.

MMC Overview on New World Evidence Data Market Report

The non-identical approach of Reports and Insights stands with conceptual methods backed up with the data analysis. The novel market understanding approach makes up the standard of the assessment results that give a better opportunity for the customers to put their effort.

A research report on the New World Evidence Data market by Reports and Insights is an in-depth and extensive study of the market based on the necessary data crunching and statistical analysis. It provides a brief view of the dynamics flowing through the market, which includes the factors that support the market and the factors that are acting as impedance for the growth of the market.

Furthermore, the report includes the various trends and opportunities in the respective market in different regions for a better understanding of readers that helps to analyze the potential of the market.

Factors that are benchmarked while estimating the market

Various factors that are benchmarked while estimating the market growth include (but not restricted to):

•    New product designs and launches

•    Current product compliance

•    Reimbursement

•    Concerns for use of New World Evidence Data

•    Advantages of New World Evidence Data

Actions taken by the manufacturer and respective regulatory authorities also impact the market growth of the segment. These factors are understood at a regional level and in major countries globally for providing regional insights into the product segment in the report. This helps our clients to make an informed decision.

A mix of top-down and bottom-up approach is followed to arrive at and validate our market value estimations. For a product segment like wherein one/two manufacturer(s) dominates the market, its product sales, previous growth rates, and market expansion plans are considered to generate market share in the global market.


To learn more about this report, request a free sample copy


1.    Global New World Evidence Data Market Report Overview

1.1.    Introduction

1.2.    Report Description

1.3.    Methodology

2.    Global New World Evidence Data Market Overview

2.1.    Introduction

2.1.1.    Introduction

2.1.2.    Market Taxonomy

2.2.    Executive Summary

2.3.    Global New World Evidence Data Market Snapshot

2.4.    Global New World Evidence Data Market Size and Forecast, 2020–2028

2.4.1.    Introduction

2.4.2.    Market Value Forecast and Annual Growth Rate (AGR) Comparison (2020–2028)

2.5.    Global New World Evidence Data Market Dynamics

2.5.1.    Drivers

2.5.2.    Restraints

2.5.3.    Opportunity

2.5.4.    Trends

2.6.    Key Regulations

2.7.    Porter’s Five Forces Model

3.    Global New World Evidence Data Market, By Components

3.1.    Introduction

3.1.1.    Annual Growth Rate Comparison, By Components

3.1.2.    BPS Analysis, By Components

3.2.    Market Revenue (US$Mn) Forecast, By Components

3.2.1.    Dataset (Claims, Clinical, Pharmacy, Patient), 

3.2.2.    Services

3.3.    Global New World Evidence Data Market Attractiveness Index, By Components

4.    Global New World Evidence Data Market, By Therapeutic Area

4.1.    Introduction

4.1.1.    Annual Growth Rate Comparison, By Therapeutic Area

4.1.2.    BPS Analysis, By Therapeutic Area

4.2.    Market Revenue (US$Mn) Forecast, By Therapeutic Area

4.2.1.    Oncology

4.2.2.    Cardiovascular

4.2.3.    Immunology

4.3.    Global New World Evidence Data Market Attractiveness Index, By Therapeutic Area

5.    Global New World Evidence Data Market, By End User

5.1.    Introduction

5.1.1.    Annual Growth Rate Comparison, By End User

5.1.2.    BPS Analysis, By End User

5.2.    Market Revenue (US$Mn) Forecast, By End User

5.2.1.    Pharmaceuticals

5.2.2.    Medical Devices

5.2.3.    Payers

5.2.4.    Providers

5.3.    Global New World Evidence Data Market Attractiveness Index, By End User

6.    Global New World Evidence Data Market, By Region

6.1.    Introduction

6.1.1.    Annual Growth Rate Comparison, By Region

6.1.2.    BPS Analysis, By Region

6.2.    Market Revenue (US$Mn) Forecast, By Region

6.2.1.    North America

6.2.2.    Latin America

6.2.3.    Europe

6.2.4.    Asia Pacific

6.2.5.    Middle East

6.2.6.    Africa

6.3.    Global New World Evidence Data Market Attractiveness Index, By Region

7.    North America New World Evidence Data Market Analysis and Forecast, 2020–2028

7.1.    Introduction

7.1.1.    Annual Growth Rate Comparison, By Country

7.1.2.    BPS Analysis, By Country

7.2.    Market Revenue (US$Mn) Forecast, By Country

7.2.1.    U.S. New World Evidence Data Market

7.2.2.    Canada New World Evidence Data Market

7.3.    North America New World Evidence Data Market, By Components

7.3.1.    Dataset (Claims, Clinical, Pharmacy, Patient), 

7.3.2.    Services

7.4.    North America New World Evidence Data Market, By Therapeutic Area

7.4.1.    Oncology

7.4.2.    Cardiovascular

7.4.3.    Immunology

7.5.    North America New World Evidence Data Market, By End User

7.5.1.    Pharmaceuticals

7.5.2.    Medical Devices

7.5.3.    Payers

7.5.4.    Providers

7.6.    North America New World Evidence Data Market Attractiveness Index

7.6.1.    By Country

7.6.2.    By Components

7.6.3.    By Therapeutic Area

7.6.4.    By End User

8.    Latin America New World Evidence Data Market Analysis and Forecast, 2020–2028

8.1.    Introduction

8.1.1.    Annual Growth Rate Comparison, By Country

8.1.2.    BPS Analysis, By Country

8.2.    Market (US$Mn) Forecast, By Country

8.2.1.    Brazil New World Evidence Data Market

8.2.2.    Mexico New World Evidence Data Market

8.2.3.    Argentina New World Evidence Data Market

8.2.4.    Rest of Latin America New World Evidence Data Market

8.3.    Latin America New World Evidence Data Market, By Components

8.3.1.    Dataset (Claims, Clinical, Pharmacy, Patient), 

8.3.2.    Services

8.4.    Latin America New World Evidence Data Market, By Therapeutic Area

8.4.1.    Oncology

8.4.2.    Cardiovascular

8.4.3.    Immunology

8.5.    Latin America New World Evidence Data Market, By End User

8.5.1.    Pharmaceuticals

8.5.2.    Medical Devices

8.5.3.    Payers

8.5.4.    Providers

8.6.    Latin America New World Evidence Data Market Attractiveness Index

8.6.1.    By Country

8.6.2.    By Components

8.6.3.    By Therapeutic Area

8.6.4.    By End User

9.    Europe New World Evidence Data Market Analysis and Forecast, 2020–2028

9.1.    Introduction

9.1.1.    Annual Growth Rate Comparison, By Country

9.1.2.    BPS Analysis, By Country

9.2.    Market (US$Mn) Forecast, By Country

9.2.1.    U.K. New World Evidence Data Market

9.2.2.    Germany New World Evidence Data Market

9.2.3.    Italy New World Evidence Data Market

9.2.4.    France New World Evidence Data Market

9.2.5.    Spain New World Evidence Data Market

9.2.6.    Russia New World Evidence Data Market

9.2.7.    Poland New World Evidence Data Market

9.2.8.    BENELUX New World Evidence Data Market

9.2.9.    NORDIC New World Evidence Data Market

9.2.10.    Rest of Europe New World Evidence Data Market

9.3.    Europe New World Evidence Data Market, By Components

9.3.1.    Dataset (Claims, Clinical, Pharmacy, Patient), 

9.3.2.    Services

9.4.    Europe New World Evidence Data Market, By Therapeutic Area

9.4.1.    Oncology

9.4.2.    Cardiovascular

9.4.3.    Immunology

9.5.    Europe New World Evidence Data Market, By End User

9.5.1.    Pharmaceuticals

9.5.2.    Medical Devices

9.5.3.    Payers

9.5.4.    Providers

9.6.    Europe New World Evidence Data Market Attractiveness Index

9.6.1.    By Country

9.6.2.    By Components

9.6.3.    By Therapeutic Area

9.6.4.    By End User

10.    Asia Pacific New World Evidence Data Market Analysis and Forecast, 2020–2028

10.1.    Introduction

10.1.1.    Annual Growth Rate Comparison, By Country

10.1.2.    BPS Analysis, By Country

10.2.    Market (US$Mn) Forecast, By Country

10.2.1.    China New World Evidence Data Market

10.2.2.    India New World Evidence Data Market

10.2.3.    Japan New World Evidence Data Market

10.2.4.    Australia and New Zealand New World Evidence Data Market

10.2.5.    South Korea New World Evidence Data Market

10.2.6.    ASEAN New World Evidence Data Market

10.2.7.    Rest of Asia Pacific New World Evidence Data Market

10.3.    Asia Pacific New World Evidence Data Market, By Components

10.3.1.    Dataset (Claims, Clinical, Pharmacy, Patient), 

10.3.2.    Services

10.4.    Asia Pacific New World Evidence Data Market, By Therapeutic Area

10.4.1.    Oncology

10.4.2.    Cardiovascular

10.4.3.    Immunology

10.5.    Asia Pacific New World Evidence Data Market, By End User

10.5.1.    Pharmaceuticals

10.5.2.    Medical Devices

10.5.3.    Payers

10.5.4.    Providers

10.6.    Asia Pacific New World Evidence Data Market Attractiveness Index

10.6.1.    By Country

10.6.2.    By Components

10.6.3.    By Therapeutic Area

10.6.4.    By End User

11.    Middle East New World Evidence Data Market, By Region

11.1.    Introduction

11.1.1.    Annual Growth Rate Comparison, By Country

11.1.2.    BPS Analysis, By Country

11.2.    Market (US$Mn) Forecast, By Country

11.2.1.    GCC Countries New World Evidence Data Market

11.2.2.    Israel New World Evidence Data Market

11.2.3.    Oman New World Evidence Data Market

11.2.4.    Rest of Middle East New World Evidence Data Market

11.3.    Middle East New World Evidence Data Market, By Components

11.3.1.    Dataset (Claims, Clinical, Pharmacy, Patient), 

11.3.2.    Services

11.4.    Middle East New World Evidence Data Market, By Therapeutic Area

11.4.1.    Oncology

11.4.2.    Cardiovascular

11.4.3.    Immunology

11.5.    Middle East New World Evidence Data Market, By End User

11.5.1.    Pharmaceuticals

11.5.2.    Medical Devices

11.5.3.    Payers

11.5.4.    Providers

11.6.    Middle East New World Evidence Data Market Attractiveness Index

11.6.1.    By Country

11.6.2.    By Components

11.6.3.    By Therapeutic Area

11.6.4.    By End User

12.    Africa New World Evidence Data Market, By Region

12.1.    Introduction

12.1.1.    Annual Growth Rate Comparison, By Country

12.1.2.    BPS Analysis, By Country

12.2.    Market (US$Mn) Forecast, By Country

12.2.1.    South Africa New World Evidence Data Market

12.2.2.    Egypt New World Evidence Data Market

12.2.3.    North Africa New World Evidence Data Market

12.2.4.    Rest of Africa New World Evidence Data Market

12.3.    Africa New World Evidence Data Market, By Components

12.3.1.    Dataset (Claims, Clinical, Pharmacy, Patient), 

12.3.2.    Services

12.4.    Africa New World Evidence Data Market, By Therapeutic Area

12.4.1.    Oncology

12.4.2.    Cardiovascular

12.4.3.    Immunology

12.5.    Africa New World Evidence Data Market, By End User

12.5.1.    Pharmaceuticals

12.5.2.    Medical Devices

12.5.3.    Payers

12.5.4.    Providers

12.6.    Africa New World Evidence Data Market Attractiveness Index

12.6.1.    By Country

12.6.2.    By Components

12.6.3.    By Therapeutic Area

12.6.4.    By End User

13.    Recommendation

13.1.    Market Strategy

14.    Competitive Landscape

14.1.    Competition Dashboard

14.2.    List and Company Overview of Global Key Players

14.3.    Company Profiles

14.3.1.    Oracle

14.3.1.1.    Company Overview

14.3.1.2.    Financial Overview

14.3.1.3.    Component Portfolio

14.3.1.4.    Key Developments

14.3.1.5.    Business Strategies

14.3.2.    IQVIA

14.3.3.    International Business Machines Corporation

14.3.4.    Syneos Health

14.3.5.    ICON

14.3.6.    Pharmaceutical Product Development

14.3.7.    Optum

14.3.8.    Cognizant

14.3.9.    SAS

14.3.10.    Flatiron Health

15.    Acronyms

Select License Type

Frequently Asked Questions

The global new world evidence data market in 2020 is estimated for more than US$ 883.5 Bn and expected to reach a value of US$ 2,607.4 Bn by 2028 with a significant CAGR of 14.6%.

The growing usage of the electronic health record systems as an observational system for the patient is primarily flourishing and constantly growing need for enhanced medical products and devices and increasing count of novel clinical trials for the approval of new drug products is further projected to fuel the growth of the new world evidence data market

Market is segmented on the basis of component, therapeutic area, end user and by region

Some of the key participating players in the global new world evidence data market are Oracle, IQVIA, International Business Machines Corporation, Syneos Health, ICON, Pharmaceutical Product Development, Optum, Cognizant, SAS, and Flatiron Health.



This site uses cookies, including third-party cookies, that help us to provide and improve our services. Privacy Policy

OK